
Michael F Berger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9039881/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	9.0	4
2	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	7.0	28
3	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
4	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
5	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
6	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
7	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
8	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications, 2022, 13, 1450.	12.8	47
9	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	2.8	12
10	Cancer-Causative Mutations Occurring in Early Embryogenesis. Cancer Discovery, 2022, 12, 949-957.	9.4	21
11	Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. Pathology Research and Practice, 2022, 233, 153892.	2.3	2
12	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	12.6	75
13	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
14	Targeting <i>HER2 </i> mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial Journal of Clinical Oncology, 2022, 40, 4079-4079.	1.6	11
15	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precision Oncology, 2022, , .	3.0	3
16	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	7.0	4
17	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
18	Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23

#	Article	IF	CITATIONS
19	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	7.0	15
20	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	2.8	20
21	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
22	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
23	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212
24	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
25	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
26	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	4.3	52
27	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
28	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	7.0	8
29	Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. Nature Metabolism, 2021, 3, 558-570.	11.9	58
30	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
31	Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncology, 2021, 7, 739.	7.1	125
32	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
33	Clinical Experience of Cerebrospinal Fluid–Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. Journal of Molecular Diagnostics, 2021, 23, 742-752.	2.8	17
34	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
35	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
36	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83

3

#	Article	IF	CITATIONS
37	Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.1	24
38	Association of Plasma Circulating Tumor DNA With Diagnosis of Metastatic Uveal Melanoma. JAMA Ophthalmology, 2021, 139, 1244-1245.	2.5	4
39	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. Npj Breast Cancer, 2021, 7, 124.	5.2	7
40	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	2.0	17
41	Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing. Cancers, 2021, 13, 149.	3.7	27
42	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	3.0	2
43	A quick guide for clinical oncology. Nature Cancer, 2021, 2, 998-999.	13.2	1
44	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
45	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
46	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	27.8	183
47	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	12.8	15
48	Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	7.0	60
49	PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal of Clinical Oncology, 2020, 38, 71-80.	1.6	119
50	Fumarate hydratase <i>FH</i> c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109.	2.5	25
51	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	7.1	66
52	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	1.6	60
53	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	4.1	5
54	A phase 2 trial of buparlisib in patients with platinumâ€resistant metastatic urothelial carcinoma. Cancer, 2020, 126, 4532-4544.	4.1	14

#	Article	IF	CITATIONS
55	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
56	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
57	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	3.0	9
58	Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood. journal of applied laboratory medicine, The, 2020, 5, 788-797.	1.3	6
59	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	12.8	31
60	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic <i>EGFR</i> -Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
61	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	4.1	44
62	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. Clinical Chemistry, 2020, 66, 616-618.	3.2	35
63	Cellâ€free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. Cancer Medicine, 2020, 9, 6093-6101.	2.8	32
64	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.9	18
65	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer, 2020, 126, 1995-2002.	4.1	26
66	The Clinical Management of Clonal Hematopoiesis. Hematology/Oncology Clinics of North America, 2020, 34, 357-367.	2.2	42
67	Regorafenib in Combination with First‣ine Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	3.7	10
68	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	7.0	62
69	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
70	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
71	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	7.0	135
72	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. Blood, 2020, 136, 37-38.	1.4	1

#	Article	IF	CITATIONS
73	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
74	Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients. Blood, 2020, 136, 30-31.	1.4	1
75	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer, 2019, 22, 355-362.	5.3	11
76	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
77	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
78	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
79	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
80	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	7.0	30
81	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	3.6	26
82	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.2	31
83	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	30.7	320
84	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	27.8	361
85	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	5.5	82
86	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. PLoS ONE, 2019, 14, e0217399.	2.5	12
87	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	5.5	49
88	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research, 2019, 25, 4712-4722.	7.0	292
89	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	4.5	37
90	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	2.0	38

#	Article	IF	CITATIONS
91	Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
92	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
93	Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology, 2019, 75, 29-38.	2.9	12
94	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO Precision Oncology, 2019, 3, 1-13.	3.0	6
95	Genomic Characterization of <i>ERBB2</i> -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2019, 3, 1-9.	3.0	23
96	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
97	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
98	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precision Oncology, 2019, 3, 1-9.	3.0	26
99	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	5.5	10
100	Next-Generation Sequencing–Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	2.8	19
101	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	7.1	426
102	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood, 2019, 133, 436-445.	1.4	159
103	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical Cancer Research, 2019, 25, 937-945.	7.0	22
104	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
105	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
106	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
107	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	7.0	390
108	Genomic Differences Between "Primary―and "Secondary―Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	1.9	104

#	Article	IF	CITATIONS
109	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
110	Molecular Diagnostics in Cancer: A Fundamental Component of Precision Oncology. , 2019, , 5-31.		0
111	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. Blood, 2019, 134, 2148-2148.	1.4	3
112	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	6.3	170
113	The value of cellâ€free DNA for molecular pathology. Journal of Pathology, 2018, 244, 616-627.	4.5	91
114	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
115	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
116	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
117	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	27.6	351
118	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	7.0	200
119	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
120	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
121	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	12.6	834
122	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
123	Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precision Oncology, 2018, 2018, 1-18.	3.0	39
124	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	1.6	399
125	Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
126	Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	1.6	1,109

#	Article	IF	CITATIONS
127	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
128	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
129	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	16.8	73
130	Radioactive Iodine–Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4216-4223.	3.6	33
131	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
132	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research, 2018, 24, 4154-4161.	7.0	348
133	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER \hat{i}_{\pm} enhancer function. Oncogene, 2018, 37, 4692-4710.	5.9	102
134	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
135	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
136	Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews Cancer, 2018, 18, 527-528.	28.4	34
137	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	1.5	19
138	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
139	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	1.4	10
140	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers Journal of Clinical Oncology, 2018, 36, 1504-1504.	1.6	2
141	A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
142	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225
143	An Acquired <i>HER2</i> â€~T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	9.4	85
144	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24

#	Article	IF	CITATIONS
145	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
146	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
147	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
148	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research, 2017, 23, 5970-5980.	7.0	89
149	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors. Cancer Discovery, 2017, 7, 963-972.	9.4	331
150	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130, 397-407.	1.4	112
151	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research, 2017, 23, 5366-5373.	7.0	109
152	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
153	Nextâ€generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscleâ€invasive urothelial carcinoma treated with bacille Calmetteâ€Guérin. Cancer Cytopathology, 2017, 125, 416-426.	2.4	26
154	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
155	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	5.5	74
156	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
157	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
158	The genetic landscape of endometrial clear cell carcinomas. Journal of Pathology, 2017, 243, 230-241.	4.5	168
159	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017, 23, 929-937.	30.7	146
160	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	7.0	161
161	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
162	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood, 2017, 130, 1644-1648.	1.4	82

#	Article	IF	CITATIONS
163	Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Modern Pathology, 2017, 30, 1760-1772.	5.5	67
164	Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2017, 39, e443-e445.	0.6	2
165	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	1.5	111
166	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2017, 71, 405-414.	1.9	173
167	Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer, 2017, 123, 1134-1143.	4.1	43
168	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
169	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	1.9	263
170	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology, 2017, 2017, 1-17.	3.0	209
171	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286
172	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	1.6	240
173	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
174	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	36
175	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	3.0	275
176	Precision oncology: Charting a path forward to broader deployment of genomic profiling. PLoS Medicine, 2017, 14, e1002242.	8.4	16
177	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10
178	Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. Journal of Pediatric Hematology/Oncology, 2016, 38, e166-e168.	0.6	3
179	Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes and Cancer, 2016, 55, 124-130.	2.8	38
180	Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes Chromosomes and Cancer, 2016, 55, 591-600.	2.8	58

#	Article	IF	CITATIONS
181	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	27.0	1,205
182	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica, 2016, 101, e237-e239.	3.5	17
183	Somatic <i>PIK3CA</i> mutations as a driver of sporadic venous malformations. Science Translational Medicine, 2016, 8, 332ra42.	12.4	147
184	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2016, 23, 2548-2555.	1.5	70
185	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
186	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology, 2016, 29, 476-488.	5.5	95
187	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
188	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of Clinical Oncology, 2016, 34, 2404-2415.	1.6	297
189	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	1.6	69
190	Investigation of Somatic <i>GNAQ, GNA11, BAP1</i> and <i>SF3B1</i> Mutations in Ophthalmic Melanocytomas. Ocular Oncology and Pathology, 2016, 2, 171-177.	1.0	13
191	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 4000-4007.	1.6	147
192	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	4.1	50
193	Delivering on the promise of precision cancer medicine. Genome Medicine, 2016, 8, 110.	8.2	7
194	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	12.8	140
195	A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer, 2016, 99, 23-30.	2.0	57
196	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e81-e90.	1.9	4
197	The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Modern Pathology, 2016, 29, 1058-1069.	5.5	82
198	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374.	1.5	49

#	Article	IF	CITATIONS
199	Profiling Non–Small Cell Lung Cancer: From Tumor to Blood. Clinical Cancer Research, 2016, 22, 790-792.	7.0	14
200	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	7.1	270
201	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	21.4	143
202	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.4	36
203	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets. Clinical Cancer Research, 2016, 22, 3618-3629.	7.0	342
204	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation, 2016, 126, 1052-1066.	8.2	874
205	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	1.4	16
206	Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma. Blood, 2016, 128, 4115-4115.	1.4	0
207	Comprehensive mutation profiling by nextâ€generation sequencing of effusion fluids from patients with highâ€grade serous ovarian carcinoma. Cancer Cytopathology, 2015, 123, 289-297.	2.4	25
208	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	5.2	30
209	Consistent copy number changes and recurrent <scp><i>PRKAR1A</i></scp> mutations distinguish <scp>M</scp> elanotic <scp>S</scp> chwannomas from <scp>M</scp> elanomas: <scp>SNP</scp> â€array and next generation sequencing analysis. Genes Chromosomes and Cancer, 2015, 54, 463-471.	2.8	44
210	Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e175-e182.	3.8	47
211	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	1.8	103
212	Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma. Modern Pathology, 2015, 28, 1023-1032.	5.5	69
213	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	12.8	605
214	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 1313-1320.	7.0	240
215	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology, 2015, 28, 1123-1129.	5.5	51
216	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. Cancer Discovery, 2015, 5, 842-849.	9.4	514

#	Article	IF	CITATIONS
217	GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. Journal of the American College of Surgeons, 2015, 220, 845-854e1.	0.5	154
218	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	3.7	57
219	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discovery, 2015, 5, 610-621.	9.4	129
220	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	2.8	1,566
221	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
222	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
223	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2015, 373, 1733-1747.	27.0	281
224	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	6.4	136
225	Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature, 2015, 518, 240-244.	27.8	486
226	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. Blood, 2015, 126, 449-449.	1.4	3
227	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	2.5	38
228	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	1.8	12
229	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
230	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	1.4	1
231	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature Communications, 2014, 5, 3116.	12.8	521
232	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genetics, 2014, 46, 424-426.	21.4	291
233	Synthetic Lethality in ATM-Deficient <i>RAD50</i> -Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	9.4	114
234	PRADA: pipeline for RNA sequencing data analysis. Bioinformatics, 2014, 30, 2224-2226.	4.1	147

#	ARTICLE	IF	CITATIONS
235	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	21.4	472
236	Detection of Mutations in Myeloid Malignancies through Paired-Sample Analysis of Microdroplet-PCR Deep Sequencing Data. Journal of Molecular Diagnostics, 2014, 16, 504-518.	2.8	26
237	Hematopoietic Stem Cell Origin of <i>BRAF</i> V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	12.4	102
238	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Molecular Oncology, 2014, 8, 150-158.	4.6	37
239	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	17.5	1,785
240	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	4.1	169
241	Harnessing massively parallel DNA sequencing for the personalization of cancer management. Personalized Medicine, 2013, 10, 183-190.	1.5	2
242	Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing. Journal of Visualized Experiments, 2013, , e50710.	0.3	61
243	Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. Blood, 2013, 122, 2876-2876.	1.4	4
244	High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing. Cancer Discovery, 2012, 2, 82-93.	9.4	484
245	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	12.6	681
246	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	27.8	671
247	The genomic complexity of primary human prostate cancer. Nature, 2011, 470, 214-220.	27.8	1,107
248	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of Clinical Oncology, 2011, 29, 3085-3096.	1.6	890
249	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	Ο